65 results on '"Igdem S"'
Search Results
2. The Application of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning: Effect on Gross Target Volume Definition and Treatment Management
- Author
-
İğdem, Ş., Alço, G., Ercan, T., Ünalan, B., Kara, B., Geceer, G., Akman, C., Zengin, F.O., Atilla, S., and Okkan, S.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
3. Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy: TROD 09-001 multi-institutional study [Behandlungsergebnisse von mit definitiver Strahlentherapie behandelten Prostatakrebspatienten mit einem Gleason-Score von 8–10: TROD 09-001 Multizenterstudie]
- Author
-
Ozyigit G., Onal C., Igdem S., Alicikus Z.A., Iribas A., Akin M., and Dincbas F.
- Subjects
Pelvic radiotherapy ,Grading system ,Hormonal treatment ,Intensity modulated radiation therapy ,Androgen deprivation therapy - Abstract
PubMed: 31143994, 2-s2.0-85071184712, Purpose: To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8–10 disease treated with external beam radiotherapy (EBRT)?+ androgen deprivation therapy (ADT) in the modern era. Methods: Institutional databases of biopsy proven 641 patients with GS 8–10 PCa treated between 2000 and 2015 were collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. The inclusion criteria were, T1–T3N0M0 disease according to AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70?Gy total irradiation dose to prostate?± seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated RT and patients receiving ADT. Results: The median follow-up time was 5.9 years (range 0.4–18.2 years); 5?year overall survival (OS), biochemical relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively. Higher RT doses (?78?Gy) and longer ADT duration (?2 years) were significant predictors for improved DMFS, whereas advanced stage was a negative prognosticator for DMFS in patients with GS 9–10. Conclusions: Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with GS 8 versus those with GS 9–10 prostate cancer. We found that EBRT dose was important predictive factor regardless of ADT period. Patients receiving ‘non-optimal treatment’ (RT doses more...
- Published
- 2019
4. RESULTS OF STEREOTACTIC RADIATION THERAPY (SABR) IN EARLY STAGE LUNG CANCER: TURKISH RADIATION ONCOLOGY GROUP (TROG) STUDY
- Author
-
Atalar, B., Saglam, E. Kaytan, Akgun, Z., Abacioglu, U., Arifoglu, A., Sahin, B., Enis Ozyar, Yaprak, G., Isik, N. Ozseker, Ozkok, H. Caglar, Karaman, S., Igdem, S., Selek, U., Dincbas, F. Oner, Sengoz, M., Yucel, S. Baskaya, Demiral, A. Nur, and Akyurek, S. more...
- Published
- 2018
5. The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study
- Author
-
Akyol, F., Ozyigit, G., Onal, C., Igdem, S., Alicikus, Z. Arican, Iribas, A., Akin, M., YALMAN, DENİZ, Cetin, I., Aksu, M. G., Atalar, B., DİNÇBAŞ, Hidayet Fazilet, Darendeliler, E., Ozkok, S., Korcum, A. F., Agaoglu, F. Y., Gorken, I. B., Yildirim, C., SERT, FATMA, Aydin, B., Ege Üniversitesi, and Acibadem University Dspace more...
- Abstract
WOS: 000467786301348
- Published
- 2017
6. Proceedings of the 7th Biannual International Symposium on Nasopharyngeal Carcinoma 2015
- Author
-
Tan, IB, Chang, Ellen T., Chen, Chien-Jen, Hsu, Wan-Lun, Chien, Yin-Chu, Hildesheim, Allan, McKay, James D., Gaborieau, Valerie, Kaderi, Mohamed Arifin Bin, Purnomosari, Dewajani, Voegele, Catherine, LeCalvez-Kelm, Florence, Byrnes, Graham, Brennan, Paul, Devi, Beena, Li, L., Zhang, Y., Fan, Y., Sun, K., Du, Z., Sun, H., Chan, A. T., Tsao, S. W., Zeng, Y. X., Tao, Q., Busson, Pierre, Lhuillier, Claire, Morales, Olivier, Mrizak, Dhafer, Gelin, Aurore, Kapetanakis, Nikiforos, Delhem, Nadira, Mansouri, Sheila, Cao, Jennifer, Vaidya, Anup, Frappier, Lori, Wai, Lo Kwok, Chen, Sui-Hong, Du, Jin-lin, Ji, Ming-Fang, Huang, Qi-Hong, Liu, Qing, Cao, Su-Mei, Doolan, Denise L., Coghill, Anna, Mulvenna, Jason, Proietti, Carla, Lekieffre, Lea, Bethony, Jeffrey, Hildesheim, and Allan, Fles, Renske, Indrasari, Sagung Rai, Herdini, Camelia, Martini, Santi, Isfandiari, Atoillah, Rhomdoni, Achmad, Adham, Marlinda, Mayangsari, Ika, van Werkhoven, Erik, Wildeman, Maarten, Hariwiyanto, Bambang, Hermani, Bambang, Kentjono, Widodo Ario, Haryana, Sofia Mubarika, Schmidt, Marjanka, O’Sullivan, Brian, Ozyar, Enis, Lee, Anne W. M., Zeng, Mu-Sheng, Gao, Xiaojiang, Tang, Minzhong, Martin, Pat, Zeng, Yi, Carrington, Mary, Coghill, Anna E., Bu, Wei, Nguyen, Hanh, Yu, Kelly J., Lou, Pei-Jen, Wang, Cheng-Ping, Cohen, Jeffrey I., King, Ann D., Chen, Tseng-Cheng, Lin, Ching-Yuan, Tsou, Yung-An, Leu, Yi-Shing, Laio, Li-Jen, Chang, Yen-Liang, Hua, Chun-Hun, Wu, Ming-Shiang, Hsiao, Chu-Hsing Kate, Lee, Jehn-Chuan, Tsai, Ming-Hsui, Cheng, Skye Hung-Chun, Liao, Li-Jen, Yang, Tsung-Lin, Ko, Jenq-Yuh, Ko, Josephine Mun Yee, Dai, Wei, Kwong, Dora, Ng, Wai Tong, Lee, Anne, Ngan, Roger Kai Cheong, Yau, Chun Chung, Tung, Stewart, Lung, Maria Li, Ji, Mingfang, Sheng, Wei, Ng, Mun Hon, Cheng, Weimin, Yu, Xia, Wu, Biaohua, Wei, Kuangrong, Zhan, Jun, Zeng, Yi Xin, Cao, Su Mei, Xia, Ningshao, Yuan, Yong, Cui, Qian, Xu, Miao, Bei, Jin-Xin, Zeng, Yi-Xin, Şahin, B, Dizman, A, Esassolak, M, İkizler, A Saran, Yıldırım, HC, Çaloğlu, M, Atalar, B, Akman, F, Demiroz, C, Atasoy, BM, Canyilmaz, E, Igdem, S, Ugurluer, G, Kütük, T, Akmansoy, M, Ozyar, E, Sommat, Kiattisa, Wang, Fu Qiang, Kwok, Li-Lian, Tan, Terence, Fong, Kam Weng, Soong, Yoke Lim, Cheah, Shie Lee, Wee, Joseph, Casanova, M, Özyar, E, Patte, C, Orbach, D, Ferrari, A, Cristine, VF, Errihani, H, Pan, J, Zhang, L, Liji, S, Grzegorzewski, K, Gore, L, Varan, A, Hutajulu, Susanna Hilda, Khuzairi, Guntara, Kusumo, Henry, Hardianti, Mardiah Suci, Taroeno-Hariadi, Kartika Widayati, Purwanto, Ibnu, Kurnianda, Johan, Messick, Troy E., Malecka, Kimberly, Tolvinski, Lois, Soldan, Samantha, Deakyne, Julianna, Song, Hui, van den Heuvel, Antonio, Gu, Baiwei, Cassel, Joel, McDonnell, Mark, Smith, Garry R., Velvadapu, Venkata, Bian, Haiyan, Zhang, Yan, Carlsen, Marianne, Chen, Shuai, Donald, Alastair, Lemmen, Christian, Reitz, Allen B., Lieberman, Paul M., Chan, King Chi, Chan, Lai Sheung, Lo, Kwok Wai, Yip, Timothy Tak Chun, Kahn, Michael, Mak, Nai Ki, Liu, Fei-Fei, Khaali, Wafa, Thariat, Juliette, Fantin, Laurence, Spirito, Flavia, Khyatti, Meriem, Driss, El Khalil Ben, Olivero, Sylvain, Maryanski, Janet, Doglio, Alain, Xia, Mengxue, Xia, Yunfei, Chang, Hui, Shaw, Rachel, Rahaju, Pudji, Wisesa, Sindhu, Taroeno-Harijadi, Kartika Widayati, Dhamiyati, Wigati, Tan, Sang-Nee, Sim, Sai-Peng, Yusuf, Muhtarum, Romdhoni, Ahmad C., K, Widodo Ario, Rantam, Fedik Abdul, Sugiyanto, Aryati, Lina, Adi-Kusumo, Fajar, Bintoro, SY, Oktriani, R., Herawati, C., Surono, A., Haryana, Sofia M., Zhong, L., Ma, B. B., Kalra, M., Ngo, M., Perna, S., Leen, A., Lapteva, N., Rooney, C. M., Gottschalk, S., Mustikaningtyas, Elida, Herawati, Sri, Romdhoni, Achmad C., Xu, Yarui, Ge, Shengxiang, Li, Fugui, Ng, M. H., Tan, Louise SY, Wong, Benjamin, Lim, C. M., Rantam, Fedik A., Madani, Deasy Z., Akbar, Nur, Permana, Agung Dinasti, Fachiroh, Jajah, Hartati, Dwi, Rahayudjati, T. Baning, Darwis, Iswandi, Anwar, Khoirul, Dwidanarti, Sri Retna, Pramana, Dominicus Wendhy, Safitri, Diah Ari, Danarti, Sri Retna Dwi, Taroeno, Suryo A, Wijaya, I., Oehadian, A., Prasetya, D., Yu, Kelly J, Rahman, Sukri, Budiman, Bestari J., Novialdi, Rahmadona, Lestari, Dewi Yuri, Yin, C., Foussadier, A., Blein, E., Chen, C., Ammour, N. Bournet, Khiatti, M., Cao, S., Marzaini, Dewi Syafriyetti Soeis, Rahayujati, Baning, Gunawan, L., Mubarika Haryana, S., Hartono, Michael, Intansari, Umi, Paramita, Dewi Kartikawati, Akbar, Akmal, Hermawan, Benny, Paramita, Dewi K., Argy, Gabriella, Sihotang, Theodora Caroline, Wahyono, Daniel Joko, Soeharso, Purnomo, Suryandari, Dwi Anita, Lisnawati, Musa, Zanil, Daker, Maelinda, Tzen, Yeo Jiun, Bakar, Norhasimah, Rahman, Asma’ Saiyidatina Aishah Abdul, Ahmad, Munirah, Chia, Yeo Tiong, Beng, Alan Khoo Soo, Sasikirana, Widyandani, Wardana, Tirta, Radifar, Muhammad, Herawati, Cita, Surono, Agus, and Çocuk Sağlığı ve Hastalıkları more...
- Subjects
Meeting Abstracts - Abstract
A1 Hope and despair in the current treatment of nasopharyngeal cancer, IB Tan, I1 NPC international incidence and risk factors, Ellen T Chang, I2 Familial nasopharyngeal carcinoma and the use of biomarkers, Chien-Jen Chen, Wan-Lun Hsu, Yin-Chu Chien, I3 Genetic susceptibility risk factors for sporadic and familial NPC: recent findings, Allan Hildesheim, I5 Genetic and environmental risk factors for nasopharyngeal cancer in Southeast Asia, James D McKay, Valerie Gaborieau, Mohamed Arifin Bin Kaderi, Dewajani Purnomosari, Catherine Voegele, Florence LeCalvez-Kelm, Graham Byrnes, Paul Brennan, Beena Devi, I6 Characterization of the NPC methylome identifies aberrant epigenetic disruption of key signaling pathways and EBV-induced gene methylation, Li L, Zhang Y, Fan Y, Sun K, Du Z, Sun H, Chan AT, Tsao SW, Zeng YX, Tao Q, I7 Tumor exosomes and translational research in NPC, Pierre Busson, Claire Lhuillier, Olivier Morales, Dhafer Mrizak, Aurore Gelin, Nikiforos Kapetanakis, Nadira Delhem, I8 Host manipulations of the Epstein-Barr virus EBNA1 protein, Sheila Mansouri, Jennifer Cao, Anup Vaidya, and Lori Frappier, I9 Somatic genetic changes in EBV-associated nasopharyngeal carcinoma, Lo Kwok Wai, I10 Preliminary screening results for nasopharyngeal carcinoma with ELISA-based EBV antibodies in Southern China, Sui-Hong Chen, Jin-lin Du, Ming-Fang Ji, Qi-Hong Huang, Qing Liu, Su-Mei Cao, I11 EBV array platform to screen for EBV antibodies associated with NPC and other EBV-associated disorders, Denise L. Doolan, Anna Coghill, Jason Mulvenna, Carla Proietti, Lea Lekieffre, Jeffrey Bethony, and Allan Hildesheim, I12 The nasopharyngeal carcinoma awareness program in Indonesia, Renske Fles, Sagung Rai Indrasari, Camelia Herdini, Santi Martini, Atoillah Isfandiari, Achmad Rhomdoni, Marlinda Adham, Ika Mayangsari, Erik van Werkhoven, Maarten Wildeman, Bambang Hariwiyanto, Bambang Hermani, Widodo Ario Kentjono, Sofia Mubarika Haryana, Marjanka Schmidt, IB Tan, I13 Current advances and future direction in nasopharyngeal cancer management, Brian O’Sullivan, I14 Management of juvenile nasopharyngeal cancer, Enis Ozyar, I15 Global pattern of nasopharyngeal cancer: correlation of outcome with access to radiotherapy, Anne WM Lee, I16 The predictive/prognostic biomarker for nasopharyngeal carcinoma, Mu-Sheng Zeng, I17 Effect of HLA and KIR polymorphism on NPC risk, Xiaojiang Gao, Minzhong Tang, Pat Martin, Yi Zeng, Mary Carrington, I18 Exploring the Association between Potentially Neutralizing Antibodies against EBV Infection and Nasopharyngeal Carcinoma, Anna E Coghill, Wei Bu, Hanh Nguyen, Wan-Lun Hsu, Kelly J Yu, Pei-Jen Lou, Cheng-Ping Wang, Chien-Jen Chen, Allan Hildesheim, Jeffrey I Cohen, I19 Advances in MR imaging in NPC, Ann D King, O1 Epstein-Barr virus seromarkers and risk of nasopharyngeal carcinoma: the gene-environment interaction study on nasopharyngeal carcinoma in Taiwan, Yin-Chu Chien, Wan-Lun Hsu, Kelly J Yu, Tseng-Cheng Chen, Ching-Yuan Lin, Yung-An Tsou, Yi-Shing Leu, Li-Jen Laio, Yen-Liang Chang, Cheng-Ping Wang, Chun-Hun Hua, Ming-Shiang Wu, Chu-Hsing Kate Hsiao, Jehn-Chuan Lee, Ming-Hsui Tsai, Skye Hung-Chun Cheng, Pei-Jen Lou, Allan Hildesheim, Chien-Jen Chen, O2 Familial tendency and environmental co-factors of nasopharyngeal carcinoma: the gene-environment interaction study on nasopharyngeal carcinoma in Taiwan, Wan-Lun Hsu, Kelly J Yu, Yin-Chu Chien, Tseng-Cheng Chen, Ching-Yuan Lin, Yung-An Tsou, Yi-Shing Leu, Li-Jen Liao, Yen-Liang Chang, Tsung-Lin Yang, Chun-Hun Hua, Ming-ShiangWu, Chu-Hsing Kate Hsiao, Jehn-ChuanLee, Ming-Hsui Tsai, Skye Hung-Chun Cheng, Jenq-Yuh Ko, Allan Hildesheim, Chien-Jen Chen, O3 The genetic susceptibility and prognostic role of TERT-CLPTM1L and genes in DNA damage pathways in NPC, Josephine Mun Yee Ko, Wei Dai, Dora Kwong, Wai Tong Ng, Anne Lee, Roger Kai Cheong Ngan, Chun Chung Yau, Stewart Tung, Maria Li Lung, O4 Long term effects of NPC screening, Mingfang Ji, Wei Sheng, Mun Hon Ng, Weimin Cheng, Xia Yu, Biaohua Wu, Kuangrong Wei, Jun Zhan, Yi Xin Zeng, Su Mei Cao, Ningshao Xia, Yong Yuan, O5 Risk prediction of nasopharyngeal carcinoma by detecting host genetic and Epstein-Barr virus variation in saliva, Qian Cui, Miao Xu, Jin-Xin Bei, Yi-Xin Zeng, O6 Patterns of care study in Turkish nasopharyngeal cancer patients (NAZOTURK): A Turkish Radiation Oncology Association Head and Neck Cancer Working Group Study, B Şahin, A Dizman, M Esassolak, A Saran İkizler, HC Yıldırım, M Çaloğlu, B Atalar, F Akman, C Demiroz, BM Atasoy, E Canyilmaz, S Igdem, G Ugurluer, T Kütük, M Akmansoy, E Ozyar, O7 Long term outcome of intensity modulated radiotherapy in nasopharyngeal carcinoma in National Cancer Centre Singapore, Kiattisa Sommat, Fu Qiang Wang, Li-Lian Kwok, Terence Tan, Kam Weng Fong, Yoke Lim Soong, Shie Lee Cheah, Joseph Wee, O8 International phase II randomized study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents, M Casanova, E Özyar, C Patte, D Orbach, A Ferrari, VF Cristine, H Errihani, J Pan, L Zhang, S Liji, K Grzegorzewski, L Gore, A Varan, O9 Prognostic impact of metastatic status in patients with nasopharyngeal carcinoma, Susanna Hilda Hutajulu, Guntara Khuzairi, Camelia Herdini, Henry Kusumo, Mardiah Suci Hardianti, Kartika Widayati Taroeno-Hariadi, Ibnu Purwanto, Johan Kurnianda, O10 Development of small molecule inhibitors of latent Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma, Troy E. Messick, Kimberly Malecka, Lois Tolvinski, Samantha Soldan, Julianna Deakyne, Hui Song, Antonio van den Heuvel, Baiwei Gu, Joel Cassel, Mark McDonnell, Garry R Smith, Venkata Velvadapu, Haiyan Bian, Yan Zhang, Marianne Carlsen, Shuai Chen, Alastair Donald, Christian Lemmen, Allen B Reitz, Paul M Lieberman, O11 Therapeutic targeting of cancer stem-like cells using a Wnt modulator, ICG-001, enhances the treatment outcome of EBV-positive nasopharyngeal carcinoma, King Chi Chan, Lai Sheung Chan, Kwok Wai Lo, Timothy Tak Chun Yip, Roger Kai Cheong Ngan, Michael Kahn, Maria Li Lung, Nai Ki Mak, O12 Role of micro-RNA in NPC biology, Fei-Fei Liu, O13 Expansion of EBNA1- and LMP2-specific effector T lymphocytes from patients with nasopharyngeal carcinoma without enhancement of regulatory T cells, Wafa Khaali; Juliette Thariat; Laurence Fantin; Flavia Spirito; Meriem Khyatti; El Khalil Ben Driss; Sylvain Olivero; Janet Maryanski; Alain Doglio, O14 The experience of patients’ life after amifostine radiotherapy treatment (ART) for nasopharyngeal carcinoma (NPC), Mengxue Xia, Yunfei Xia, Hui Chang, Rachel Shaw, O15 Analysis of mitochondrial DNA mutation in latent membrane protein-1 positive nasopharyngeal carcinoma, Pudji Rahaju, O16 Factors influencing treatment adherence of nasopharyngeal cancer and the clinical outcomes: a hospital-based study, Mardiah Suci Hardianti, Sindhu Wisesa, Kartika Widayati Taroeno-Harijadi, Ibnu Purwanto, Bambang Hariwiyanto, Wigati Dhamiyati, Johan Kurnianda, O17 Chromosomal breaks mediated by bile acid-induced apoptosis in nasopharyngeal epithelial cells: in relation to matrix association region/scaffold attachment region, Sang-Nee Tan, Sai-Peng Sim, O18 Expression of p53 (wild type) on nasopharyngeal carcinoma stem cell that resistant to radiotherapy, Muhtarum Yusuf, Ahmad C Romdhoni, Widodo Ario K, Fedik Abdul Rantam, O19 Mathematical model of nasopharyngeal carcinoma in cellular level, Sugiyanto, Lina Aryati, Fajar Adi-Kusumo, Mardiah Suci Hardianti, O20 Differential expression of microRNA-21 on nasopharyngeal carcinoma plasma patient, SY Bintoro, R Oktriani, C. Herawati, A Surono, Sofia M. Haryana, O21 Therapeutic targeting of an oncogenic fibroblast growth factor-FGF19, which promotes proliferation and induces EMT of carcinoma cells through activating ERK and AKT signaling, L. Zhong, L. Li, B. B. Ma, A. T. Chan, Q. Tao, O22 Resist nasopharyngeal carcinoma (NPC): next generation T cells for the adoptive immunotherapy of NPC, M. Kalra, M. Ngo, S. Perna, A. Leen, N. Lapteva, C. M. Rooney, S. Gottschalk, O23 The correlation of heat shock protein 70 expressions and staging of nasopharyngeal carcinoma, Elida Mustikaningtyas, Sri Herawati, Achmad C Romdhoni, O24 Epstein-Barr virus serological profiles of nasopharyngeal carcinoma - A tribute to Werner Henle, Mingfang Ji, YaruiXu, Weimin Cheng, ShengxiangGe, Fugui Li, M. H. Ng, O25 Targeting the apoptosis pathway using combination TLR3 agonist with anti-survivin molecule (YM-155) in nasopharyngeal carcinoma, Louise SY Tan, Benjamin Wong, CM Lim, O26 The resistance mechanism of nasopharyngeal cancer stem cells to cisplatin through expression of CD44, Hsp70, p53 (wild type), Oct-4, and ß-catenin encoded-genes, Achmad C Romdhoni, Fedik A. Rantam, Widodo Ario Kentjono, P1 Prevalence of nasopharyngeal carcinoma patients at Departement of Otorhinolaringology-Head and Neck Surgery, Dr. Hasan Sadikin general hospital, Bandung, Indonesia in 2010-2014, Deasy Z Madani, Nur Akbar, Agung Dinasti Permana, P2 Case report on pediatric nasopharyngeal carcinoma at Dr. Sardjito Hospital, Yogyakarta, Camelia Herdini, Sagung Rai Indrasari, Jajah Fachiroh, Dwi Hartati, T. Baning Rahayudjati, P3 Report on loco regionally advanced nasopharyngeal cancer patients treated with induction chemotherapy followed by concurrent chemo-radiation therapy, Iswandi Darwis, Susanna Hilda Hutajulu, Bambang Hariwiyanto, Wigati Dhamiyati, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, P4 Sex and age differences in the survival of patients with nasopharyngeal carcinoma, Sindhu Wisesa, Mardiah Suci Hardianti, Susanna Hilda Hutajulu, Kartika Widayati Taroeno-Harijadi, Ibnu Purwanto, Camelia Herdini, Wigati Dhamiyati, Johan Kurnianda, P5 Impact of delayed diagnosis and delayed therapy in the treatment outcome of patients with nasopharyngeal carcinoma, Khoirul Anwar, Susanna Hilda Hutajulu, Sagung Rai Indrasari, Sri Retna Dwidanarti, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, P6 Anaysis of pretreatment anemia in nasopharyngeal cancer patients undergoing neoadjuvant therapy, Dominicus Wendhy Pramana, Susanna Hilda Hutajulu, Bambang Hariwiyanto, Wigati Dhamiyati, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, P7 Results of treatment with neoadjuvant cisplatin-5FU in locally advanced nasopharyngeal carcinoma: a local experience, Diah Ari Safitri, Susanna Hilda Hutajulu, Camelia Herdini, Sri Retna Dwi Danarti, Ibnu Purwanto, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, P8 Geriatrics with nasopharyngeal cancer, Suryo A Taroeno, Sindhu Wisesa, Kartika Widayati Taroeno-Hariadi, Ibnu Purwanto, Bambang Hariwiyanto, Wigati Dhamiyati, Johan Kurnianda, P9 Correlation of lymphocyte to monocyte and neutrophil to lymphocyte ratio to the response of cisplatin chemoradiotheraphy in locally advance nasopharyngeal carcinoma, I. Wijaya, A. Oehadian, D. Prasetya, P10 Prediction of nasopharyngeal carcinoma risk by Epstein-Barr virus seromarkers and environmental co-factors: the gene-environment interaction study on nasopharyngeal carcinoma in Taiwan, Wan-Lun Hsu, Yin-Chu Chien, Kelly J Yu, Cheng-Ping Wang, Ching-Yuan Lin, Yung-An Tsou, Yi-Shing Leu, Li-Jen Liao, Yen-Liang Chang191,192, Jenq-Yuh Ko, Chun-Hun Hua, Ming-Shiang Wu, Chu-Hsing Kate Hsiao, Jehn-Chuan Lee, Ming-Hsui Tsai, Skye Hung-Chun Cheng, Pei-Jen Lou, Allan Hildesheim, Chien-Jen Chen, P11 Non-viral risk factors for nasopharyngeal carcinoma in West Sumatra, Indonesia, Sukri Rahman, Bestari J. Budiman, Novialdi, Rahmadona, Dewi Yuri Lestari, P12 New prototype Vidas EBV IgA quick: performance on Chinese and Moroccan populations, C. Yin, A. Foussadier, E. Blein, C. Chen, N. Bournet Ammour, M. Khiatti, S. Cao, P13 The expression of EBV-LMP1 and VEGF as predictors and plasma EBV-DNA levels as early marker of distant metastasis after therapy in nasopharyngeal cancer, Dewi Syafriyetti Soeis Marzaini, P14 Characteristics and factors influencing subjects refusal for blood samples retrieval: lesson from NPC case control study in Yogyakarta – Indonesia, Dwi Hartati, Baning Rahayujati, Camelia Herdini, Jajah Fachiroh, P15 Expression of microRNA BART-7-3p and mRNA PTEN on blood plasma of patients with nasopharyngeal carcinoma, L. Gunawan, S. Mubarika Haryana, A. Surono, C. Herawati, P16 IgA response to native early antigen (IgA-EAext) of Epstein-Barr virus (EBV) in healthy population and nasopharyngeal carcinoma (NPC) patients: the potential for diagnosis and screening tools, Michael Hartono, Jajah Fachiroh, Umi Intansari, Dewi Kartikawati Paramita, P17 IgA responses against Epstein-Barr Virus Early Antigen (EBV-EA) peptides as potential candidates of nasopharyngeal carcinoma detection marker, Akmal Akbar, Jajah Fachiroh, Dewi Kartikawati Paramita, P18 Association between smoking habit and IgA-EBV titer among healthy individuals in Yogyakarta, Indonesia, Benny Hermawan, T Baning Rahayudjati, Dewi K Paramita, Jajah Fachiroh, P19 Epstein-Barr virus IgA titer comparison of healthy non-family individuals and healthy first degree family of NPV patients, Gabriella Argy, Jajah Fachiroh, Dewi Kartikawati Paramita, Susanna Hilda Hutajulu, P20 Identification of EBV Early Antigen (EA) derived peptides for NPC diagnosis, Theodora Caroline Sihotang, Jajah Fachiroh, Umi Intansari, Dewi Kartikawati Paramita, P21 Host-pathogen study: relative expression of mRNA BRLF1 Epstein-Barr virus as a potential biomarker for tumor progressivity and polymorphisms of TCRBC and TCRGC2 host genes related to genetic susceptibility on nasopharyngeal carcinoma, Daniel Joko Wahyono, Purnomo Soeharso, Dwi Anita Suryandari, Lisnawati, Zanil Musa, Bambang Hermani, P22 In vitro efficacy of silvestrol and episilvestrol, isolated from Borneo, on nasopharyngeal carcinoma, a major cancer in Borneo, Maelinda Daker, Yeo Jiun Tzen, Norhasimah Bakar, Asma’ Saiyidatina Aishah Abdul Rahman, Munirah Ahmad, Yeo Tiong Chia, Alan Khoo Soo Beng, P23 The expression of mir-141 in patients with nasopharyngeal cancer, Widyandani Sasikirana, Tirta Wardana, Muhammad Radifar, Cita Herawati, Agus Surono, Sofia Mubarika Haryana more...
- Published
- 2016
7. EP-1532 Metastases directed SBRT using Ga68-PSMA for oligometastatic prostate cancer: TROD 09-002 Study
- Author
-
Ozyigit, G., Igdem, S., Atalar, B., Ozkok, H.B., Hurmuz, P., and Akyol, F.
- Published
- 2019
- Full Text
- View/download PDF
8. P2.16-14 Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study
- Author
-
Atalar, B., Kaytan Sağlam, E., Akgün, Z., Abacioglu, U., Arifoglu, A., Sahin, B., Ozyar, E., Yaprak, G., Ozseker Isik, N., Caglar Ozkok, H., Karaman, S., Igdem, S., Selek, U., Öner Dincbas, F., Sengoz, M., Başkaya Yucel, S., Nur Demiral, A., and Akyurek, S. more...
- Published
- 2018
- Full Text
- View/download PDF
9. PO-0734: The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study
- Author
-
Ozyigit, G., Onal, C., Igdem, S., Arican Alicikus, Z., Iribas, A., Akin, M., Yalman, D., Cetin, I., Aksu, M.G., Atalar, B., Dincbas, F., Aydin, B., Sert, F., Yildirim, C., Gorken, I.B., Agaoglu, F.Y., Korcum, A.F., Ozkok, S., Darendeliler, E., and Akyol, F. more...
- Published
- 2017
- Full Text
- View/download PDF
10. 284P - Do Young Age and Triple Negative Molecular Subtype Have a Negative Effect on Survival in Patients with Early Stage Breast Cancer?
- Author
-
Ordu, C., Bozdogan, A., Alco, G., Pilanci, K.N., Selamoglu, D., Agacayak, F., Erdogan, Z., Ilgun, S., Elbuken, F., Igdem, S., Okkan, S., and Ozmen, V.
- Published
- 2014
- Full Text
- View/download PDF
11. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
- Author
-
Erpolat, O. P., Alco, G., Caglar, H. B., Igdem, S., Saran, A., Dagoglu, N., Aslay, I., Ozsaran, Z., Demirci, S., Keven, E., Guney, Y., Akmansu, M., Kilic, D., Bayman, E., Etiz, D., and Mandel, N. M.
- Abstract
Purpose: To compare the incidence and severity of acute and chronic hematologic toxicity (HT) in patients treated with three-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) for curative treatment of cervical cancer and to ascertain the dosimetric parameters of two techniques associated with acute and chronic HT. Materials and Methods: A total of 127 patients with cervical cancer receiving concomitant pelvic radiotherapy (RT) and cisplatin were evaluated. Pelvic bone marrow (BM) was contoured for each patient and divided into five sub-regions: lumbosacrum (LS), ilium (IL), lower pelvis (LP), pelvis (P), and whole pelvis (WP). The volume of each BM region receiving 10,20,30, and 40 Gy was calculated (V10, -V20, -V30, and -V40). The lowest level of hemoglobin, leukocyte, neutrophil, and platelet counts were obtained during chemoradiotherapy and six months after RT. The nadir values were graded according to Common Terminology Criteria for Adverse Events (version 3.0). Results: Grade 2 or greater acute anemia, leukopenia, neutropenia, thrombocytopenia was observed in 2%, 41.5%, 12%,and 0% in 3DCRT group and in 27%, 53%, 24.5%, and 4.5% in IMRT group, respectively. Grade 2 or greater chronic anemia, leukopenia, neutropenia, and thrombocytopenia was observed in 11%, 10%, 6%, and 0% in 3DCRT group and in 11%, 9%, 4.5%, and 0% in IMRT group, respectively. LSV30,40; IL-VI 0,20,30,40; LP-V10,20,40; P-V10,20,30,40, and TP-V10,20,30,40 were significantly reduced with IMRT planning compared to 3DCRT planning. Logistic regression analysis of potential predictors showed that none of the dosimetric parameters were significant for predicting acute and chronic HT. Conclusion: The present findings showed that IMRT planning reduced irradiated BM volumes compared to 3DCRT planning. However, no difference between the two techniques was observed in terms of acute and chronic HT. Further studies are needed to confirm these results. [ABSTRACT FROM AUTHOR] more...
- Published
- 2014
- Full Text
- View/download PDF
12. Dosimetric comparison of field in field intensity-modulated radiotherapy technique with conformal radiotherapy techniques in breast cancer.
- Author
-
Ercan T, Igdem S, Alço G, Zengin F, Atilla S, Dinçer M, Okkan S, Ercan, Tülay, Iğdem, Sefik, Alço, Gül, Zengin, Funda, Atilla, Selin, Dinçer, Maktav, and Okkan, Sait
- Abstract
Purpose: The aim of this study was to be able to implement the field-in-field intensity-modulated radiotherapy (FiF) technique in our daily practice for breast radiotherapy. To do this, we performed a dosimetric comparison.Materials and Methods: Treatment plans were produced for 20 consecutive patients. FiF plans and conformal radiotherapy (CRT) plans were compared for doses in the planning target volume (PTV), the dose homogeneity index (DHI), doses in irradiated soft tissue outside the target volume (SST), ipsilateral lung and heart doses for left breast irradiation, and the monitor unit counts (MU) required for treatment. Averaged values were compared using Student's t-test.Results: With FiF, the DHI is improved 7.0% and 5.7%, respectively (P < 0.0001) over the bilateral and lateral wedge CRT techniques. When the targeted volumes received 105% and 110% of the prescribed dose in the PTV were compared, significant decreases are found with the FiF technique. With the 105% dose, the SST, heart, and ipsilateral lung doses and the MU counts were also significantly lower with the FiF technique.Conclusion: The FiF technique, compared to CRT, for breast radiotherapy enables significantly better dose distribution in the PTV. Significant differences are also found for soft tissue volume, the ipsilateral lung dose, and the heart dose. Considering the decreased MUs needed for treatment, the FiF technique is preferred over tangential CRT. [ABSTRACT FROM AUTHOR] more...- Published
- 2010
- Full Text
- View/download PDF
13. DOSIMETRIC AND CLINICAL EVALUATION OF BRACHIAL PLEX-OPATHY IN PATIENTS WITH HEAD AND NECK CANCER TREATED WITH INTENSITY MODULATED RADIOTHERAPY
- Author
-
Igdem, S., Hanagasi, F., Solakoglu, C., Alço, G., Ercan, T., Altun, M., Turkan, S., and Okkan, S.
- Published
- 2011
- Full Text
- View/download PDF
14. DOSIMETRIC COMPARISON OF FIELD IN FIELD INTENSITY MODULATED RADIOTHERAPY TECHNIQUE WITH CONFORMAL RADIOTHERAPY TECHNIQUES IN BREAST CANCER
- Author
-
Ercan, T., Igdem, S., Alço, G., Zengin, F., Ozgules, R., Atilla, S., Dincer, M., and Okkan, S.
- Published
- 2009
- Full Text
- View/download PDF
15. 5531 POSTER PET/CT guided IMRT in head and neck cancer: impact on treatment planning and local control: Early results
- Author
-
Alco, G., Igdem, S., Kara, B., Ünalan, B., Ercan, T., Altun, M., Turkan, S., and Okkan, S.
- Published
- 2007
- Full Text
- View/download PDF
16. Replacement of Tumor Bed After Oncoplastic Breast-Conserving Surgery With Immediate Latissimus Dorsi Mini-flap.
- Author
-
Alco, G., Igdem, S., Okkan, S., Dincer, M., Agacayak, F., Selamoglu, D., Ilgun, S., and Ozmen, V.
- Subjects
- *
LUMPECTOMY , *LATISSIMUS dorsi physiology , *BREAST cancer patients , *BREAST cancer treatment , *CANCER radiotherapy - Published
- 2014
- Full Text
- View/download PDF
17. Pretreatment SUVmax as a Prognostic Factor in Patients With Nasopharyngeal Cancer Treated With IMRT
- Author
-
Igdem, S., Altun, M., Alço, G., Ercan, T., Ünalan, B., Turkan, S., and Okkan, S.
- Published
- 2012
- Full Text
- View/download PDF
18. Patient Reported Toxicity in Men Treated with 3D Conformal Techniques for Localized Prostate Cancer: A Turkish Oncology Group (TOG) Study
- Author
-
Igdem, S., Alco, G., Oner Dincbas, F., Abacioglu, U., Kilic, D., Yalman, D., Elicin, O., Ibrahimov, R., Demirci, S., and Okkan, S.
- Published
- 2011
- Full Text
- View/download PDF
19. Whole Field Simultaneous Integrated Boost IMRT in Nasopharyngeal Cancer
- Author
-
Igdem, S., Altun, M., Alço, G., Ercan, T., Tecimer, C., Köksal, G., Gürses, K., Demir, G., and Okkan, S.
- Published
- 2010
- Full Text
- View/download PDF
20. Prostatic Duct Adenocarcinoma: Clinical Characteristics, Treatment Options and Outcomes: A Rare Cancer Network Study
- Author
-
Igdem, S., Spiegel, D., Efstathiou, J., Zietman, A., Miller, R., Poortmans, P., and Unsal, D.
- Published
- 2009
- Full Text
- View/download PDF
21. PET/CT Guided, Dose Painting IMRT for Nasopharyngeal Carcinoma
- Author
-
Igdem, S., Altun, M., Alço, G., Ercan, T., Kara, B., Ünalan, B., Tecimer, C., Köksal, G., Turkan, S., and Okkan, S.
- Published
- 2008
- Full Text
- View/download PDF
22. Dosimetric Parameters of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With Concurrent Cisplatin and Pelvic Radiation Therapy: Turkish Oncology Group Gynecological Tumor Subgroup Study
- Author
-
Erpolat, P., Alco, G., Igdem, S., Aslay, N. Dagoglu I., Demirci, Z. Ozsaran S., Guney, E. Keven Y., Kılıc, M. Akmansu D., Etiz, E. Bayman D., and Mandel, N. Molinas
- Published
- 2012
- Full Text
- View/download PDF
23. Outcomes Of Carotid Sparing Radiotherapy For Early Stage Glottic Cancer: Turkish Society For Radiation Oncology Group (TROD) Retrospective Study.
- Author
-
Bicakci, B.C., Mustafayev, T.Z., Cetinayak, O., Igdem, S., Birgi, S. Duru, Meydan, D., Demircioglu, F., Atalar, B., Ozyar, E., and Akman, F.
- Subjects
- *
LARYNGEAL cancer , *TUMOR classification , *VOLUMETRIC-modulated arc therapy - Published
- 2020
- Full Text
- View/download PDF
24. Medically Inoperable Early-Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy (SABR): Multicenter Study of Turkish Radiation Oncology Group (TROG).
- Author
-
Atalar, B., Kaytan Saglam, E., Akgun, Z., Abacioglu, U., Arifoglu, A., Şahin, B., Ozyar, E., Yaprak, G., Ozseker, N., Kocak, E., Karaman, S., Igdem, S., Selek, U., Dincbas, H.F., Sengoz, M., Yucel, S.B., Demiral, A.N., and Akyurek, S. more...
- Published
- 2018
- Full Text
- View/download PDF
25. Patterns of Care Study in Turkish Nasopharyngeal Cancer Patients (NAZOTURK): A Turkish Radiation Oncology Association Head and Neck Cancer Working Group Study.
- Author
-
Ozyar, E., Dizman, A., Esassolak, M., Ikizler, A., Yildirim, C., Caloglu, M., Atalar, B., Akman, F., Demiroz, C., Atasoy, B.M., Can, E., Igdem, S., Ugurluer, G., Kutuk, T., Akmansu, M., and Sahin, B.
- Subjects
- *
NASOPHARYNX cancer patients , *CANCER radiotherapy , *MEDICAL physics , *HEALTH outcome assessment , *RADIATION doses - Published
- 2015
- Full Text
- View/download PDF
26. Survey of IMRT Practices in Centers Participating in the International Evaluation of Radiotherapy Technology Effectiveness in Cervical Cancer (IntERTECC) Trial
- Author
-
Jensen, L., Mahantshetty, U., Shi, M., Albuquerque, K., Sirák, I., Pande, S., Kim, Y., Khorprasert, C., Harris, E., and Igdem, S.
- Published
- 2011
- Full Text
- View/download PDF
27. Primary Pineal Tumors; Outcome and Prognostic Factors: A Study from the Rare Cancer Network (RCN)
- Author
-
Villa, S., Miller, R.C., Krengli, M., Abousaris, H., Baumert, B.O., Servagi-Vernat, S., Igdem, s., Lucas, A., Boluda, S., and Mirimanoff, R.O.
- Published
- 2008
- Full Text
- View/download PDF
28. Gamma Knife radiosurgery for the treatment of trigeminal neuralgia: A single center-experience.
- Author
-
Akcakaya MO, Mirkhasilova M, Ozturk O, Ugurlar D, Tonge M, Alco G, Ercan T, Igdem S, and Karadereler S
- Subjects
- Humans, Middle Aged, Female, Aged, Male, Aged, 80 and over, Adult, Treatment Outcome, Retrospective Studies, Follow-Up Studies, Recurrence, Trigeminal Neuralgia surgery, Trigeminal Neuralgia radiotherapy, Radiosurgery methods
- Abstract
Introduction and Objectives: We aimed to assess the outcomes of patients with trigeminal neuralgia (TGN) who underwent Gamma Knife radiosurgery (GKRS)., Materials and Methods: Fifty-three patients with typical TGN underwent GKRS from May 2012 until December 2022. Among these patients, 45 patients who were follow-up for at least 12 months were included in the study. A mean dose of 87.5 Gy (range, 80-90) was administered to the trigeminal nerve. Postoperatively, outcome was considered excellent if the patient was pain- and medication-free., Results: The mean symtpom duration was 9.53 years, and the mean patient age was 59.8 years (range, 34-85). The mean follow-up period was 46.8 months (range, 12-127 months). 46.7% of patients had a history of previous surgical interventions. A single nerve division was affected in 14 patients (31.1%), and multiple divisions were affected in 31 patients (68.9%). The rate of initial pain relief was 80%. Hypoesthesia in the area of trigeminal nerve developed in 30 (66.7%). Twenty patients (44.4%) exhibited excellent results within 72.4 months. Recurrence occurred in 11 patients (24.4%) with 27.6 months., Conclusions: Our results suggest that GKRS is a safe and effective procedure. Thus, it is an attractive first- and second-line treatment choice for TGN., (Copyright © 2024 Sociedad Española de Neurocirugía. Published by Elsevier España, S.L.U. All rights reserved.) more...
- Published
- 2024
- Full Text
- View/download PDF
29. A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001).
- Author
-
Yildirim HC, Kupik GE, Mustafayev TZ, Berber T, Yavuz B, Cetinayak O, Akagunduz O, Bıcakcı BC, Arslan SA, Soykut ED, Gundog M, Figen M, Teke F, Canyilmaz E, Birgi SD, Duzova M, İgdem S, Abakay CD, Atasoy B, Kaydihan N, Parvizi M, Uslu GH, Saginc H, Akman F, and Ozyar E more...
- Subjects
- Humans, Male, Middle Aged, Female, Nasopharyngeal Carcinoma pathology, Retrospective Studies, Turkey, Neoplasm Recurrence, Local pathology, Chemoradiotherapy, Neoplasm Staging, Radiotherapy, Intensity-Modulated, Nasopharyngeal Neoplasms pathology, Radiation Oncology
- Abstract
Background: We aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population., Methods: In a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed., Results: Median age was 48 (9-83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III-IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6-78) months follow-up, 8.2% locoregional and 8% distant relapse were observed. Three-year overall survival was 89.5% and was lower in patients with age ≥50, male sex, keratinizing histology, T4, N3 and advanced stage (III-IVA)., Conclusions: Patients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower., (© 2023 Wiley Periodicals LLC.) more...
- Published
- 2023
- Full Text
- View/download PDF
30. Ductal prostate cancer: Clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature.
- Author
-
Cozzi S, Bardoscia L, Najafi M, Igdem S, Triggiani L, Magrini SM, Botti A, Guedea F, Melocchi L, Ciammella P, Iotti C, and Gutierrez C
- Abstract
Objective: The aim of the study is to evaluate clinical features and outcomes after different therapeutic strategies for ductal prostate adenocarcinoma (DPC), a rare but aggressive subtype of invasive prostate cancer (PCa) accounting for, in the pure and mixed form, 1% or less and 5% or less, respectively, of all the newly diagnosed PCa., Materials and Methods: Patients with a proven diagnosis of DPC undergoing surgery, radiotherapy, and androgen deprivation therapy, alone or in combination, were considered for this multicenter, retrospective study. The study assessed overall survival (OS), disease-free survival (DFS), and age-related disease-specific survival., Results: Eighty-one patients met the study inclusion criteria. Pure DPC was found in 29 patients (36%) and mixed ductal-acinar-PCa in 52 patients (64%). After a median follow-up of 63 months (range, 3-206 months), 3- and 5-year OS rates were 84% and 67%, respectively, and 3- and 5-year DFS rates were 54% and 34%, respectively. There were no significant differences in OS or DFS between the pure and mixed DPC groups. Pure DPC was associated with a higher rate of metastatic disease at onset. Patients 74 years or younger had better disease-specific survival ( p =0.0019). A subgroup analysis favored radiotherapy as the primary treatment for nonmetastatic, organ-confined DPC (3- and 5-year DFS of 80% and 50%, respectively, compared with 5-year DFS of 35% for surgical patients; p = 0.023)., Conclusions: Our study found DPC to be rarer, more aggressive, more likely to metastasize, and have a worse prognosis than the common acinar variant, especially in its pure form. Multicenter series are encouraged to obtain large data sets, or propensity score matching analyses with patients with conventional PCa are desirable to understand the best therapeutic approach and improve outcomes., Competing Interests: The authors have declared they have no conflicts of interest., (Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc.) more...
- Published
- 2022
- Full Text
- View/download PDF
31. Outcomes of carotid sparing intensity-modulated radiotherapy for early stage glottic cancer in 201 patients: Multicenter study of Turkish Radiation Oncology Society/TROD-01-007.
- Author
-
Bicakci BC, Mustafayev TZ, Cetinayak O, Igdem S, Birgi SD, Meydan D, Demircioglu F, Atalar B, Ozyar E, and Akman F
- Subjects
- Humans, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Retrospective Studies, Laryngeal Edema, Laryngeal Neoplasms radiotherapy, Radiation Oncology, Radiotherapy, Intensity-Modulated adverse effects, Radiotherapy, Intensity-Modulated methods
- Abstract
Background: To assess and report clinical outcomes after carotid sparing intensity-modulated radiotherapy for early stage laryngeal cancer., Methods: We retrospectively analyzed 201 patients with early stage glottic laryngeal cancer treated with carotid sparing intensity-modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) techniques in six TROD centers., Results: After a median follow-up of 31 months the actuarial 1- and 3-year local and locoregional control rates were 99.4% and 94.7%, 98.4% and 93%, respectively. T classification, anterior commissure involvement, IMRT technique, and type of fractionation were not found to be prognostic for local control. Overall, eight patients had lost their organ function due to recurrence or toxicity. Grade 3 and 4 acute laryngeal edema was seen in eight (4%) and one (0.5%) of patients, respectively. Grade 3 and 4 late laryngeal edema developed in two (1%) and one patient (0.5%), respectively., Conclusion: Oncologic outcomes of patients treated with carotid sparing IMRT were excellent; comparable with historical series, with acceptable side effects. Longer follow-up is needed to estimate long term effect on stroke., (© 2022 Wiley Periodicals LLC.) more...
- Published
- 2022
- Full Text
- View/download PDF
32. Evaluation of Nutritional Status and Anxiety Levels in Patients Applying to the Radiation Oncology Outpatient Clinic during the COVID-19 Pandemic: Turkish Society for Radiation Oncology Group Study (TROD 12:02).
- Author
-
Yurut Caloglu V, Akmansu M, Yalman D, Karabulut Gul S, Kocak Z, Arican Alicikus Z, Serarslan A, Akyurek S, Zoto Mustafayev T, Demiroz C, Colpan Oksuz D, Kanyilmaz G, Altinok P, Kaytan Saglam E, Yentek Balkanay A, Akboru H, Keven E, Yildirim B, Onal C, Igdem S, Ozkan E, Ozdener F, and Caloglu M more...
- Subjects
- Ambulatory Care Facilities, Anxiety epidemiology, Anxiety etiology, Cross-Sectional Studies, Humans, Nutrition Assessment, Nutritional Status, Pandemics, COVID-19 epidemiology, Head and Neck Neoplasms complications, Malnutrition epidemiology, Malnutrition etiology, Malnutrition therapy
- Abstract
Cancer patients often face malnutrition, which negatively affects their response to cancer treatment. This study aims to analyze the effects of the COVID-19 pandemic on nutritional status and anxiety in cancer patients with different types and stages of cancer. This is a cross-sectional cohort study that includes 1,252 patients with varying cancer types from 17 radiation oncology centers. The nutritional risk scores (NRS-2002) and coronavirus anxiety scale (CAS) scores of all patients were measured. NRS-2002 ≥ 3 and CAS ≥ 5 were accepted as values at risk. Of all patients, 15.3% had NRS-2002 ≥ 3. Breast cancer was the most prevalent cancer type (24.5%) with the lowest risk of nutrition (4.9%, p < 0.001). Nutritional risk was significantly higher in patients with gastrointestinal cancer, head and neck cancer, and lung cancer ( p < 0.005) and in patients with stage IV disease ( p < 0.001). High anxiety levels (CAS ≥ 5) were significantly related to voluntary avoidance and clinical postponement of hospital visits due to the pandemic ( p < 0.001), while clinical postponement was particularly frequent among patients with NRS-2002 < 3 ( p = 0.0021). Fear and anxiety in cancer patients with COVID-19 cause hesitations in visiting hospitals, leading to disrupted primary and nutritional treatments. Thus, nutritional monitoring and treatment monitoring of cancer patients are crucial during and after radiotherapy. more...
- Published
- 2022
- Full Text
- View/download PDF
33. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
- Author
-
Onal C, Ozyigit G, Akgun Z, Atalar B, Igdem S, Oymak E, Agaoglu F, Selek U, Guler OC, Hurmuz P, Mustafayev TZ, and Akyol F
- Subjects
- Aged, Bone Neoplasms diagnostic imaging, Gallium Isotopes, Gallium Radioisotopes, Humans, Male, Middle Aged, Prostatic Neoplasms surgery, Retrospective Studies, Bone Neoplasms radiotherapy, Bone Neoplasms secondary, Castration, Edetic Acid analogs & derivatives, Oligopeptides, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms pathology, Radiosurgery
- Abstract
Purpose: To evaluate the outcomes of metastasis-directed treatment (MDT) using stereotactic body radiotherapy (SBRT) for bone-only oligometastasis (OM) detected with gallium prostate-specific membrane antigen (68Ga-PSMA) PET/CT in castration-sensitive prostate cancer (PC) patients., Methods: In this multi-institutional study, clinical data of 74 PC patients with 153 bone lesions who were undergoing MDT were retrospectively evaluated. Twenty-seven patients (36.5%) had synchronous, and 47 (63.5%) had metachronous OM. All patients had PC with 5 metastases or fewer detected by 68Ga-PSMA PET/CT and treated using SBRT with a median dose of 20 Gy. The prognostic factors for PC-specific survival (PCSS) and progression-free survival (PFS) were analyzed., Results: The median follow-up was 27.3 months. Patients with synchronous OM were older and received higher rates of androgen deprivation therapy after SBRT compared with patients with metachronous OM. The 2-year PCSS and PFS rates were 92.0% and 72.0%, respectively. A prostate-specific antigen (PSA) decline was observed in 56 patients (75.7%), and 48 (64.9%) had a PSA response defined as at least 25% decrease of PSA after MDT. The 2-year local control rate per lesion was 95.4%. In multivariate analysis, single OM and PSA response after MDT were significant predictors for better PCSS and PFS. In-field recurrence was observed in 4 patients (6.5%) with 10 lesions at a median of 13.1 months after MDT completion. No serious late toxicity was observed., Conclusions: We demonstrated that SBRT is an efficient and well-tolerated treatment option for PC patients with 5 bone-only oligometastases or fewer detected with 68Ga-PSMA PET/CT., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) more...
- Published
- 2021
- Full Text
- View/download PDF
34. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
- Author
-
Sahin B, Atalar B, Kaytan Saglam E, Akgun Z, Abacioglu U, Arifoglu A, Ozyar E, Yaprak G, Ozseker Isik N, Guney Y, Caglar HB, Karaman S, Igdem S, Selek U, Berber T, Oner Dincbas F, Sengoz M, Yucel S, Demiral AN, and Akyurek S more...
- Subjects
- Humans, Positron Emission Tomography Computed Tomography, Prognosis, Retrospective Studies, Treatment Outcome, Turkey epidemiology, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Radiation Oncology, Radiosurgery adverse effects
- Abstract
Objective: We identified factors influencing outcomes in patients with medically inoperable early stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey., Materials and Methods: We retrospectively analyzed 431 patients with stage I-II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction and biologically effective dose with an α/β ratio of 10 (BED
10 ); tumor location and treatment center were evaluated for associations with overall survival (OS), local control (LC) and toxicity., Results: Median follow-up time was 27 months (range 1-115); median SABR dose was 54 Gy (range 30-70) given in a median three fractions (range 1-10); median BED10 was 151 Gy (range 48-180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%) and <1 cm from mediastinal structures in 77 (17.9%). Response was evaluated with PET/CT in most cases at a median 3 months after SABR. Response rates were: 48% complete, 36.7% partial, 7.9% stable and 7.4% progression. LC rates were 97.1% at 1 year, 92.6% at 2 years and 91.2% at 3 years; corresponding OS rates were 92.6%, 80.6% and 72.7%. On multivariate analysis, BED10 > 100 Gy (P = .011), adenocarcinoma (P = .025) and complete response on first evaluation (P = .007) predicted favorable LC. BED10 > 120 Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1-3.2, P = .019) and tumor size (<2 cm HR 1.9, 95% CI 1.3-3, P = .003) predicted favorable OS. No grade 4-5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]) and rib fracture (1 [0.2%])., Conclusion: SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10 > 120 Gy was needed for better LC and OS for large, non-adenocarcinoma tumors., (© 2020 John Wiley & Sons Ltd.) more...- Published
- 2020
- Full Text
- View/download PDF
35. Treatment outcomes of metastasis-directed treatment using 68 Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002).
- Author
-
Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, Akgun Z, Kurt M, Ozkok HB, Selek U, Oymak E, Tilki B, Guler OC, Mustafayev TZ, Saricanbaz I, Rzazade R, and Akyol F
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma radiotherapy, Adenocarcinoma surgery, Adult, Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Combined Modality Therapy, Dose Fractionation, Radiation, Follow-Up Studies, Gallium Radioisotopes adverse effects, Gastrointestinal Diseases etiology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Positron Emission Tomography Computed Tomography adverse effects, Progression-Free Survival, Prostatic Neoplasms diagnostic imaging, Radiation Injuries etiology, Radiopharmaceuticals adverse effects, Radiosurgery adverse effects, Radiotherapy, Intensity-Modulated adverse effects, Recurrence, Retrospective Studies, Treatment Outcome, Adenocarcinoma secondary, Antigens, Surface therapeutic use, Gallium Radioisotopes therapeutic use, Glutamate Carboxypeptidase II therapeutic use, Positron Emission Tomography Computed Tomography methods, Prostatic Neoplasms radiotherapy, Radiopharmaceuticals therapeutic use, Radiosurgery methods, Radiotherapy, Intensity-Modulated methods
- Abstract
Purpose: The aim of this study was to evaluate the outcomes of
68 Ga prostate-specific membrane antigen (68 Ga-PSMA) positron-emission tomography (PET)/CT-based metastasis-directed treatment (MDT) for oligometastatic prostate cancer (PC)., Methods: In this multi-institutional study, clinical data of 176 PC patients with 353 lesions receiving MDT between 2014 and 2019 were retrospectively evaluated. All patients had biopsy proven PC with ≤5 metastases detected with68 Ga-PSMA-PET/CT. MDT was delivered with conventional fractionation or stereotactic body radiotherapy (SBRT) techniques. CTCAE v4.0 was used for acute and RTOG/EORTC Late Radiation Morbidity Scoring Schema was used for late toxicity evaluation., Results: At the time of MDT, 59 patients (33.5%) had synchronous and 117 patients (66.5%) had metachronous metastases. Median number of metastases was one and the MDT technique was SBRT in 73.3% patients. The 2‑year overall survival (OS) and progression-free survival (PFS) rates were 87.6% and 63.1%, respectively. With a median follow-up of 22.9 months, 9 patients had local recurrence at the irradiated site. The 2‑year local control rate at the treated oligometastatic site per patient was 93.2%. In multivariate analysis, an increased number of oligometastases and untreated primary PC were negative predictors for OS; advanced clinical tumor stage, untreated primary PC, BED3 value of ≤108 Gy, and MDT with conventional fractionation were negative predictors for PFS. No patient experienced grade ≥3 acute toxicity, but one patient had a late grade 3 toxicity of compression fracture after spinal SBRT., Conclusion:68 Ga-PSMA-PET/CT-based MDT is an efficient and safe treatment for oligometastatic PC patients. Proper patient selection might improve treatment outcomes. more...- Published
- 2020
- Full Text
- View/download PDF
36. Changes in radiotherapy practice during COVID-19 outbreak in Turkey: A report from the Turkish Society for Radiation Oncology.
- Author
-
Anacak Y, Onal C, Ozyigit G, Agaoglu F, Akboru H, Akyurek S, Gursel B, Igdem S, Yalman D, Yıldız F, and Kaytan Saglam E
- Published
- 2020
- Full Text
- View/download PDF
37. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study.
- Author
-
Ozyigit G, Onal C, Igdem S, Alicikus ZA, Iribas A, Akin M, Yalman D, Cetin I, Aksu MG, Atalar B, Dincbas F, Hurmuz P, Guler OC, Aydin B, Sert F, Yildirim C, Gorken IB, Agaoglu FY, Korcum AF, Yuce D, Ozkok S, Darendeliler E, and Akyol F more...
- Subjects
- Adult, Aged, Aged, 80 and over, Androgen Antagonists therapeutic use, Combined Modality Therapy, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Radiotherapy Dosage, Survival Rate, Treatment Outcome, Turkey, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8-10 disease treated with external beam radiotherapy (EBRT) + androgen deprivation therapy (ADT) in the modern era., Methods: Institutional databases of biopsy proven 641 patients with GS 8-10 PCa treated between 2000 and 2015 were collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. The inclusion criteria were, T1-T3N0M0 disease according to AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70 Gy total irradiation dose to prostate ± seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated RT and patients receiving ADT., Results: The median follow-up time was 5.9 years (range 0.4-18.2 years); 5‑year overall survival (OS), biochemical relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively. Higher RT doses (≥78 Gy) and longer ADT duration (≥2 years) were significant predictors for improved DMFS, whereas advanced stage was a negative prognosticator for DMFS in patients with GS 9-10., Conclusions: Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with GS 8 versus those with GS 9-10 prostate cancer. We found that EBRT dose was important predictive factor regardless of ADT period. Patients receiving 'non-optimal treatment' (RT doses <78 Gy and ADT period <2 years) had the worst treatment outcomes. more...
- Published
- 2019
- Full Text
- View/download PDF
38. Replacement of the tumor bed following oncoplastic breast-conserving surgery with immediate latissimus dorsi mini-flap.
- Author
-
Alço G, Igdem S, Okkan S, Dincer M, Sarsenov D, Ilgun AS, Agacayak F, Elbüken F, Ercan T, Selamoglu D, and Ozmen V
- Abstract
The aim of the present study was to evaluate the geographic variability of the tumor bed following oncoplastic breast-conserving surgery (OP-BCS), and to assess its relevance for radiotherapy planning. In this prospective study, pre- and postoperative computerized tomography (CT) scans of 22 patients with early-stage breast cancer were fused. The preoperative gross tumor volume or excisional biopsy cavity were contoured under the guidance of preoperative radiological images. Postoperative lumpectomy cavities were contoured under the guidance of surgical clips. The conformity index (CI) was calculated and defined on a scale between 0 and 1, where 0 indicated no overlap and 1 indicated 100% concordance. Associations between CI and the number of clips, time interval between surgery and CT scans, pathological tumor size and age were assessed using independent sample testing. The median CI was 0.07 (in five cases, 1, and in eight cases, 0). The lumpectomy cavity shifted from the primary location in 36.4% of the cases. Median shifts between the isocenters of pre- and postoperative volumes were measured as 1.02 cm (range, 0.4-4.43 cm) in the x, 1.07 cm (range, 0.05-5.67 cm) in the y, and 1.12 cm (range, 0-3.75 cm) in the z directions. Only the clip number was determined to be significantly associated with CI (P=0.017). Pre- and postoperative tumor bed volumes were fully superposed in five of the 22 cases. The present study has shown that the tumor bed is markedly replaced following OP-BCS with latissimus dorsi mini-flap (LDMF) reconstruction. Special care should therefore be taken when defining the lumpectomy cavity following OP-BCS with LDMF reconstruction. more...
- Published
- 2016
- Full Text
- View/download PDF
39. Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.
- Author
-
Zwahlen DR, Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Loessl K, Belkaaloul KK, Villette S, and Vees H
- Abstract
Uterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 1987-2007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (≤60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases. more...
- Published
- 2016
- Full Text
- View/download PDF
40. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients.
- Author
-
Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, Igdem S, Okkan S, Dincer M, Demir G, and Ozmen V
- Abstract
The aim of the present study was to identify the optimal Ki-67 cut-off value in breast cancer (BC) patients, and investigate the association of Ki-67 expression levels with other prognostic factors. Firstly, a retrospective search was performed to identify patients with stage I-III BC (n=462). A range of Ki-67 index values were then assigned to five groups (<10, 10-14, 15-19, 20-24 and ≥25%). The correlation between the Ki-67 index and other prognostic factors [age, tumor type, histological and nuclear grade, tumor size, multifocality, an in situ component, lymphovascular invasion (LVI), estrogen and progesterone receptor (ER/PR) expression, human epidermal growth factor receptor (HER-2) status, axillary involvement and tumor stage] were investigated in each group. The median Ki-67 value was revealed to be 20% (range, 1-95%). A young age (≤40 years old), tumor type, size and grade, LVI, ER/PR negativity and HER-2 positivity were revealed to be associated with the Ki-67 level. Furthermore, Ki-67 was demonstrated to be negatively correlated with ER/PR expression (P<0.001), but positively correlated with tumor size (P<0.001). The multivariate analysis revealed that a Ki-67 value of ≥15% was associated with the largest number of poor prognostic factors (P=0.036). In addition, a Ki-67 value of ≥15% was identified to be statistically significant in association with certain luminal subtypes. The rate of disease-free survival was higher in patients with luminal A subtype BC (P=0.036). Following the correlation analysis for the Ki-67 index and the other prognostic factors, a Ki-67 value of ≥15% was revealed to be the optimal cut-off level for BC patients. more...
- Published
- 2015
- Full Text
- View/download PDF
41. History of the rare cancer network and past research.
- Author
-
Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick U, Pehlivan B, Krengli M, Pellanda AF, Vees H, Cai L, Scandolaro L, Belkacemi Y, Villà S, Igdem S, Lutsyk M, and Miller RC
- Abstract
Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented in two companion papers. This manuscript reviews the history of the growth of the RCN and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN. more...
- Published
- 2014
- Full Text
- View/download PDF
42. Vitamin D levels in patients with breast cancer: importance of dressing style.
- Author
-
Alco G, Igdem S, Dincer M, Ozmen V, Saglam S, Selamoglu D, Erdogan Z, Ordu C, Pilanci KN, Bozdogan A, Yenice S, Tecimer C, Demir G, Koksal G, and Okkan S
- Subjects
- Adult, Aged, Body Mass Index, Breast Neoplasms prevention & control, Breast Neoplasms radiotherapy, Diabetes Mellitus epidemiology, Dietary Supplements, Diphosphonates, Female, Humans, Menopause, Middle Aged, Prognosis, Vitamin D Deficiency blood, Breast Neoplasms blood, Vitamin D blood, Vitamin D Deficiency epidemiology
- Abstract
Background: Vitamin D deficiency is a potentially modifiable risk factor that may be targeted for breast cancer (BC) prevention. It may also be related to prognosis after diagnosis and treatment. The aim of our study was to determine the prevalence of vitamin D deficiency as measured by serum 25-hydroxy vitamin D (25-OHD) levels in patients with BC and to evaluate its correlations with life-style and treatments., Materials and Methods: This study included 186 patients with stage 0-III BC treated in our breast center between 2010-2013. The correlation between serum baseline 25-OHD levels and supplement usage, age, menopausal status, diabetes mellitus, usage of bisphosphonates, body-mass index (BMI), season, dressing style, administration of systemic treatments and radiotherapy were investigated. The distribution of serum 25-OHD levels was categorized as deficient (<10ng/ ml), insufficient (10-24 ng/ml), and sufficient (25-80 ng/ml)., Results: The median age of the patients was 51 years (range: 27-79 years) and 70% of them had deficient/insufficient 25-OHD levels. On univariate analysis, vitamin D deficiency/insufficiency was more common in patients with none or low dose vitamin D supplementation at the baseline, high BMI (≥25), no bisphosphonate usage, and a conservative dressing style. On multivariate analysis, none or low dose vitamin D supplementation, and decreased sun-exposure due to a conservative dressing style were found as independent factors increasing risk of vitamin D deficiency/insufficiency 28.7 (p=0.002) and 13.4 (p=0.003) fold, respectively., Conclusions: The prevalence of serum 25-OHD deficiency/insufficiency is high in our BC survivors. Vitamin D status should be routinely evaluated for all women, especially those with a conservative dressing style, as part of regular preventive care, and they should take supplemental vitamin D. more...
- Published
- 2014
- Full Text
- View/download PDF
43. Primary pineal tumors: outcome and prognostic factors--a study from the Rare Cancer Network (RCN).
- Author
-
Villà S, Miller RC, Krengli M, Abusaris H, Baumert BG, Servagi-Vernat S, Igdem S, Lucas A, Boluda S, and Mirimanoff RO
- Subjects
- Adolescent, Adult, Aged, Chemotherapy, Adjuvant, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Male, Middle Aged, Prognosis, Treatment Outcome, Pinealoma diagnosis, Pinealoma drug therapy, Pinealoma pathology
- Abstract
Purpose: To better define outcome and prognostic factors in primary pineal tumors., Materials and Methods: Thirty-five consecutive patients from seven academic centers of the Rare Cancer Network diagnosed between 1988 and 2006 were included. Median age was 36 years. Surgical resection consisted of biopsy in 12 cases and resection in 21 (2 cases with unknown resection). All patients underwent radiotherapy and 12 patients received also chemotherapy., Results: Histological subtypes were pineoblastoma (PNB) in 21 patients, pineocytoma (PC) in 8 patients and pineocytoma with intermediate differentiation in 6 patients. Six patients with PNB had evidence of spinal seeding. Fifteen patients relapsed (14 PNB and 1 PC) with PNB cases at higher risk (p = 0.031). Median survival time was not reached. Median disease-free survival was 82 months (CI 50 % 28-275). In univariate analysis, age younger than 36 years was an unfavorable prognostic factor (p = 0.003). Patients with metastases at diagnosis had poorer survival (p = 0.048). Late side effects related to radiotherapy were dementia, leukoencephalopathy or memory loss in seven cases, occipital ischemia in one, and grade 3 seizures in two cases. Side effects related to chemotherapy were grade 3-4 leucopenia in five cases, grade 4 thrombocytopenia in three cases, grade 2 anemia in two cases, grade 4 pancytopenia in one case, grade 4 vomiting in one case and renal failure in one case., Conclusions: Age and dissemination at diagnosis influenced survival in our series. The prevalence of chronic toxicity suggests that new adjuvant strategies are advisable. more...
- Published
- 2012
- Full Text
- View/download PDF
44. Management of adenoid cystic carcinoma of the breast: a Rare Cancer Network study.
- Author
-
Khanfir K, Kallel A, Villette S, Belkacémi Y, Vautravers C, Nguyen T, Miller R, Li YX, Taghian AG, Boersma L, Poortmans P, Goldberg H, Vees H, Senkus E, Igdem S, Ozsahin M, and Jeanneret Sozzi W
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Adenoid Cystic mortality, Carcinoma, Adenoid Cystic pathology, Female, Follow-Up Studies, Humans, Mastectomy, Segmental methods, Middle Aged, Neoplasm Staging, Prognosis, Rare Diseases mortality, Rare Diseases pathology, Retrospective Studies, Survival Rate, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma, Adenoid Cystic radiotherapy, Carcinoma, Adenoid Cystic surgery, Rare Diseases radiotherapy, Rare Diseases surgery
- Abstract
Background: Mammary adenoid cystic carcinoma (ACC) is a rare breast cancer. The aim of this retrospective study was to assess prognostic factors and patterns of failure, as well as the role of radiation therapy (RT), in ACC., Methods: Between January 1980 and December 2007, 61 women with breast ACC were treated at participating centers of the Rare Cancer Network. Surgery consisted of lumpectomy in 41 patients and mastectomy in 20 patients. There were 51(84%) stage pN0 and 10 stage cN0 (16%) patients. Postoperative RT was administered to 40 patients (35 after lumpectomy, 5 after mastectomy)., Results: With a median follow-up of 79 months (range, 6-285), 5-year overall and disease-free survival rates were 94% (95% confidence interval [CI], 88%-100%) and 82% (95% CI, 71%-93%), respectively. The 5-year locoregional control (LRC) rate was 95% (95% CI, 89%-100%). Axillary lymph node dissection or sentinel node biopsy was performed in 84% of cases. All patients had stage pN0 disease. In univariate analysis, survival was not influenced by the type of surgery or the use of postoperative RT. The 5-year LRC rate was 100% in the mastectomy group versus 93% (95% CI, 83%-100%) in the breast-conserving surgery group, respectively (p = 0.16). For the breast-conserving surgery group, the use of RT significantly correlated with LRC (p = 0.03); the 5-year LRC rates were 95% (95% CI, 86%-100%) for the RT group versus 83% (95% CI, 54%-100%) for the group receiving no RT. No local failures occurred in patients with positive margins, all of whom received postoperative RT., Conclusion: Breast-conserving surgery is the treatment of choice for patients with ACC breast cancer. Axillary lymph node dissection or sentinel node biopsy might not be recommended. Postoperative RT should be proposed in the case of breast-conserving surgery., (Copyright © 2012 Elsevier Inc. All rights reserved.) more...
- Published
- 2012
- Full Text
- View/download PDF
45. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study.
- Author
-
Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, Caglar H, Ozsaran Z, Lössl K, Schleicher U, Zwahlen D, Villette S, and Vees H
- Subjects
- Adult, Aged, Aged, 80 and over, Chemotherapy, Adjuvant, Disease-Free Survival, Endometrial Neoplasms pathology, Endometrial Neoplasms therapy, Endometrial Stromal Tumors pathology, Endometrial Stromal Tumors therapy, Female, Humans, Middle Aged, Multivariate Analysis, Prognosis, Rare Diseases pathology, Rare Diseases therapy, Retrospective Studies, Sarcoma, Endometrial Stromal pathology, Sarcoma, Endometrial Stromal therapy, Survival Rate, Treatment Outcome, Young Adult, Endometrial Neoplasms mortality, Endometrial Stromal Tumors mortality, Rare Diseases mortality, Sarcoma, Endometrial Stromal mortality
- Abstract
Purpose: To provide further understanding regarding outcome and prognostic factors of endometrial stromal tumors (EST)., Methods and Materials: A retrospective analysis was performed on the records of 59 women diagnosed with EST and treated with curative intent between 1983 and 2007 in the framework of the Rare Cancer Network., Results: Endometrial stromal sarcomas (ESS) were found in 44% and undifferentiated ESS (UES) in 49% of the cases. In 7% the grading was unclear. Of the total number of patients, 33 had Stage I, 4 Stage II, 20 Stage III, and 1 presented with Stage IVB disease. Adjuvant chemotherapy was administered to 12 patients, all with UES. External-beam radiotherapy (RT) was administered postoperatively to 48 women. The median follow-up was 41.4 months. The 5-year overall survival (OS) rate was 96.2% and 64.8% for ESS and UES, respectively, with a corresponding 5-year disease-free survival (DFS) rate of 49.4% and 43.4%, respectively. On multivariate analysis, adjuvant RT was an independent prognostic factor for OS (p = 0.007) and DFS (p = 0.013). Locoregional control, DFS, and OS were significantly associated with age (≤60 vs. >60 years), grade (ESS vs. UES), and International Federation of Gynecology and Obstetrics stage (I-II vs. III-IV). Positive lymph node staging had an impact on OS (p < 0.001)., Conclusion: The prognosis of ESS differed from that of UES. Endometrial stromal sarcomas had an excellent 5-year OS, whereas the OS in UES was rather low. However, half of ESS patients had a relapse. For this reason, adjuvant treatment such as RT should be considered even in low-grade tumors. Multicenter randomized studies are still warranted to establish clear guidelines., (Copyright © 2012 Elsevier Inc. All rights reserved.) more...
- Published
- 2012
- Full Text
- View/download PDF
46. Impact of adjuvant chemoradiotherapy for rectal cancer on the long-term quality of life and late side effects: a multicentric clinical evaluation by the Turkish Oncology Group.
- Author
-
Kilic D, Yalman D, Aksu G, Atasoy BM, Igdem S, Dincbas FO, and Yalcin S
- Subjects
- Adenocarcinoma pathology, Adolescent, Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Adjuvant, Dose Fractionation, Radiation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Rectal Neoplasms pathology, Surveys and Questionnaires, Survival Rate, Turkey, Young Adult, Adenocarcinoma therapy, Antimetabolites, Antineoplastic therapeutic use, Fluorouracil therapeutic use, Neoplasm Recurrence, Local therapy, Quality of Life, Rectal Neoplasms therapy
- Abstract
Aim: Although preoperative chemoradiatherapy (CRT) has proven its benefits in terms of decreased toxicity, there is still a considerable amount of cases that do not receive postoperative CRT. Oncologists at different geographic locations still need to know the long-term effects of this treatment in order to manage patients successfully. The current paper reports on long-term quality of life (QOL) and late side effects after adjuvant CRT in rectal cancer patients from 5 centers in Anatolia., Methods: Rectal cancer patients treated with postoperative CRT with minimum 1-year follow-up and were in complete remission, were evaluated according to RTOG and LENT-SOMA scales. They were also asked to complete Turkish version of EORTCQLQ-C30 questionnaire and the CR-38 module. Each center participated with the required clinical data., Results: Two hundred and thirty patients with median age of 55 years participated and completed the study. Median follow-up time was 5 years. All patients received RT concomitant with chemotherapy. Common parameters that both increased functional health scales and yielded better symptom scores were long term interval after treatment and sphincter-saving surgery. In addition, surgery type and follow-up time were determined to be predictors of QOL scores and late toxicity grade., Conclusion: Postoperative CRT was found to have a great impact on the long term QOL and side effects in rectal cancer survivors. The factors that adversely affect these are abdominoperineal resection and shorter interval. The findings may encourage life-long follow-up and cooperation with patients, which should be mentioned during the initial counseling. more...
- Published
- 2012
- Full Text
- View/download PDF
47. Information for decision making by patients with early-stage prostate cancer: a comparison across 9 countries.
- Author
-
Feldman-Stewart D, Capirci C, Brennenstuhl S, Tong C, Abacioglu U, Gawkowska-Suwinska M, van Gils F, Heyda A, Igdem S, Macias V, Grillo IM, Moynihan C, Pijls-Johannesma M, Parker C, Pimentel N, and Wördehoff H more...
- Subjects
- Humans, Internationality, Male, Surveys and Questionnaires, Decision Making, Prostatic Neoplasms psychology
- Abstract
Purpose: To describe decisional roles of patients with early-stage prostate cancer in 9 countries and to compare the information they rated important for decision making (DM)., Method: A survey of recently treated patients was conducted in Canada, Italy, England, Germany, Poland, Portugal, Netherlands, Spain, and Turkey. Participants indicated their decisional role in their actual decision and the role they would prefer now. Each participant also rated (essential/desired/no opinion/avoid) the importance of obtaining answers, between diagnosis and treatment decision, to each of 92 questions. For each essential/desired question, participants specified all purposes for that information (to help them: understand/decide/plan/not sure/other)., Results: A total of 659 patients participated with country-specific response rates between 58%-77%. Between 83%-96% of each country's participants recalled actually taking an active decisional role and, in most countries, that increased slightly if they were to make the decision today; there were no significant differences among countries. There was a small reliable difference in the mean number of questions rated essential for DM across countries. More striking, however, was the wide variability within each country: no question was rated essential for DM by even 50% of its participants but almost every question was rated essential by some., Conclusions: Almost all participants from each country want to participate in their treatment decisions. Although there are country-specific differences in the amount of information required, wide variation within each country suggests that information that patients feel is essential or desired for DM should be addressed on an individual basis in all countries. more...
- Published
- 2011
- Full Text
- View/download PDF
48. Information needs of early-stage prostate cancer patients: a comparison of nine countries.
- Author
-
Feldman-Stewart D, Capirci C, Brennenstuhl S, Tong C, Abacioglu U, Gawkowska-Suwinska M, van Gils F, Heyda A, Igdem S, Macias V, Grillo IM, Moynihan C, Pijls-Johannesma M, Parker C, Pimentel N, and Wördehoff H more...
- Subjects
- Aged, Humans, Male, Prostatic Neoplasms radiotherapy, Retrospective Studies, Health Knowledge, Attitudes, Practice, Prostatic Neoplasms psychology, Surveys and Questionnaires
- Abstract
Background and Purpose: Providing information to patients can improve their medical and psychological outcomes. We sought to identify core information needs common to most early-stage prostate cancer patients in participating countries., Material and Methods: Convenience samples of patients treated 3-24 months earlier were surveyed in Canada, England, Italy, Germany, Poland, Portugal, Netherlands, Spain, and Turkey. Each participant rated the importance of addressing each of 92 questions in the diagnosis-to-treatment decision interval (essential/desired/no opinion/avoid). Multivariate modelling determined the extent of variance accounted by covariates, and produced an unbiased prediction of the proportion of essential responses for each question., Results: Six hundred and fifty-nine patients responded (response rates 45-77%). On average, 35-53 questions were essential within each country; similar questions were essential to most patients in most countries. Beyond cross-country similarities, each country showed wide variability in the number and which questions were essential. Multivariate modelling showed an adjusted R-squared with predictors country, age, education, and treatment group of only 6% of the variance. A core of 20 questions were predicted to be essential to >2/3 of patients., Conclusions: Core information can be identified across countries. However, providing the core should only be a first step; each country should then provide information tailored to the needs of the individual patient., ((c) 2010 Elsevier Ireland Ltd. All rights reserved.) more...
- Published
- 2010
- Full Text
- View/download PDF
49. Implantation of fiducial markers for image guidance in prostate radiotherapy: patient-reported toxicity.
- Author
-
Igdem S, Akpinar H, Alço G, Agaçayak F, Turkan S, and Okkan S
- Subjects
- Aged, Aged, 80 and over, Biopsy, Humans, Male, Middle Aged, Pain diagnosis, Pain Measurement methods, Prostatic Neoplasms pathology, Surveys and Questionnaires, Ultrasonography, Interventional methods, Gold, Pain etiology, Prostatic Neoplasms radiotherapy, Prostheses and Implants adverse effects
- Abstract
The purpose of this study was to evaluate patient-reported morbidity of implanted fiducial markers used for image guidance in prostate radiotherapy. Three fiducial markers were implanted under transrectal ultrasound guidance to 177 patients who were referred to our department for definitive radiotherapy between June 2005 and January 2008. No local anaesthesia was administered. Patients were asked to complete a questionnaire about the possible side effects of this invasive procedure. 135 patients completed the questionnaire at a median of 57 weeks after the procedure. Pain during the procedure was assessed with the Wong-Baker Faces Pain Rating Scale. Patients were also asked to compare the pain with the diagnostic biopsy. Although haematuria, rectal bleeding and fever were reported by 15%, 4% and 2% of the 135 patients, respectively, no major toxicity necessitating any intervention was observed. The mean pain score reported by the patients was 1.7 (range, 0-5). 87% of patients reported less (or comparable) pain than the diagnostic biopsy. In conclusion, implantation of fiducial markers for image guidance in prostate radiotherapy is a safe and well-tolerated procedure. more...
- Published
- 2009
- Full Text
- View/download PDF
50. Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.
- Author
-
Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, and Okkan S
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Humans, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local radiotherapy, Neoplasm Staging, Prognosis, Prostatic Neoplasms mortality, Radiotherapy Dosage, Retrospective Studies, Survival Rate, Treatment Outcome, Androgen Antagonists therapeutic use, Prostate-Specific Antigen blood, Prostatic Neoplasms drug therapy, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: To identify the prognostic factors for biochemical outcome in patients with localized prostatic adenocarcinoma treated with external beam radiotherapy (EBRT) with or without androgen deprivation (AD) and to investigate the impact of percent positive prostate core biopsies (PCB%)., Methods: From 1998 through 2003, 333 patients with newly diagnosed localized prostate cancer were retrospectively analyzed. The patients were treated in two institutions with definitive EBRT to a median dose of 72 Gy and 80% of them received short- or long-term AD. Biochemical failure was defined using ASTRO criteria with 3 consecutive rises in prostate specific antigen (PSA)., Results: Median follow up was 36 months. Gleason score, initial PSA, risk grouping, PCB%, AD and total duration of AD were found to be significant predictors for biochemical outcome in univariate analysis. Independent predictors for PSA failure on multivariate analysis were PCB% and duration of AD. Among 3 risk groups, in the intermediate risk group the biochemical control was significantly better in patients with < 67% positive core biopsies. In the subgroup analysis of patients who received a prostatic dose
or= 67% positive core biopsies. These significant differences did not exist in patients receiving > 70.2 Gy and long-term hormonal therapy., Conclusion: Our results suggest that high PCB% could be a predictor of biochemical relapse, especially in the intermediate risk group. The role of PCB% in prostate cancer should be investigated in further trials. more...- Published
- 2009
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.